90604-02-7

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(Diphenylmethyl)-3-hydroxyazetidine hydrochloride is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity allow for the development of new drugs with potential therapeutic properties.
Used in Medicinal Chemistry Research:
1-(Diphenylmethyl)-3-hydroxyazetidine hydrochloride is used as a research tool in medicinal chemistry to explore its potential as a therapeutic agent. Its unique structure and biological activity make it an interesting compound for studying its interactions with biological targets and evaluating its efficacy in treating various diseases.
Used in Drug Development:
1-(Diphenylmethyl)-3-hydroxyazetidine hydrochloride is used in drug development to create new pharmaceuticals with potential therapeutic benefits. Its enhanced solubility in water due to the hydrochloride salt form makes it more suitable for certain pharmaceutical applications, such as oral administration or formulation in liquid dosage forms.

InChI:InChI=1/C16H17NO.ClH/c18-15-11-17(12-15)16(13-7-3-1-4-8-13)14-9-5-2-6-10-14;/h1-10,15-16,18H,11-12H2;1H

Upstream product

• 91-00-9 Benzhydrylamine 
• 106-89-8 epichlorohydrin 
• 5267-34-5 aminodiphenylmethane hydrochloride 
• 98-17-9 3-Trifluoromethylphenol 
• 1643-19-2 tetrabutylammomium bromide 
• 124-63-0 methanesulfonyl chloride 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 63477-43-0 3-chloro-1-diphenylmethylamino-2-hydroxypropane 

Downstream Products

• 132924-40-4 3-[3-(fluoro)phenoxy]azetidine oxalate 
• 106859-45-4 1-(Diphenylmethyl)-3-azetidinol methanesulfonate (ester) hydrochloride 
• 40320-60-3 N-benzhydryl 3-azetidinone 
• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 1025713-55-6 tert-butyl 2-[1-(diphenylmethyl)azetidin-3-ylidene]hydrazinecarboxylate 
• 1025713-57-8 tert-butyl 2-[1-(diphenylmethyl)azetidin-3-yl] hydrazinecarboxylate 
• 1025899-41-5 1-benzhydryl-3-hydrazinylazetidine 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 934665-18-6 1-(diphenylmethyl)-3-hydroxyazetidine-3-carboxamide 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 
• 365997-70-2 1-benzhydryl-3-(tert-butyl-diphenyl-silanyloxy)-azetidine 
• 36476-82-1 1-(diphenylmethyl)-3-methoxyazetidine 
• 18621-18-6 azetion-3-ol hydrochloride 

Relevant academic research and scientific papers

PROCESSES OF PREPARING A JAK1 INHIBITOR

The present application provides processes for preparing 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H, 1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, and phosphoric acid salt thereof, which is useful as a selective (Janus kinase 1) JAK1 inhibitor, as well as salt forms and intermediates related thereto.

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR

This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors

Phosphodiesterase 9A inhibitors have shown activity in preclinical models of cognition with potential application as novel therapies for treating Alzheimers disease. Our clinical candidate, PF-04447943 (2), demonstrated acceptable CNS permeability in rats with modest asymmetry between central and peripheral compartments (free brain/free plasma = 0.32; CSF/free plasma = 0.19) yet had physicochemical properties outside the range associated with traditional CNS drugs. To address the potential risk of restricted CNS penetration with 2 in human clinical trials, we sought to identify a preclinical candidate with no asymmetry in rat brain penetration and that could advance into development. Merging the medicinal chemistry strategies of structure-based design with parallel chemistry, a novel series of PDE9A inhibitors was identified that showed improved selectivity over PDE1C. Optimization afforded preclinical candidate 19 that demonstrated free brain/free plasma ≥1 in rat and reduced microsomal clearance along with the ability to increase cyclic guanosine monophosphosphate levels in rat CSF.

AMINO-HETEROCYCLIC COMPOUNDS

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS

Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+,K+-ATPase. They are useful for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.

Syntheses and pharmacokinetic studies of prodrug esters for the development of oral carbapenem, L-084

We discovered an orally active carbapenem, L-084, through pharmacokinetic studies on various prodrug esters of (1R,5S,6S)-6-[(R)-1-hydroxyethyl]-1-methyl- 2-[1-(1,3-thiazolin-2-yl)azetidin-3-yl]thio-1-carbapen-2-em-3-carboxylic acid (LJC11,036). L-084 showed a strong antimicrobial activity against Gram-positive and Gram-negative bacteria and exhibited the highest intestinal absorption among synthesized prodrugs of LJC11,036. Japan Antibiotics Research Association.

Derivatives of heterocycles with 5 members, their preparation and their use as medicaments

The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives of general formula (I) wherein Het is thiazole, oxazole, imidazole, isoxazole or isoxazoline, n is an integer from 0 to 6, A is notably selected from various optionally substituted aromatic radicals, B is notably hydrogen, alkyl or phenyl, R1 and R2 are notably independently hydrogen, alkyl or cycloalkyl and Ω is —NR46R47 or —OR48 R46 and R47 are notably independently hydrogen, alkyl, cycloalkyl or —(CH2)k—COOR51, R51 is notably alkyl or haloalkyl and R48 is notably hydrogen or alkyl. These compounds have advantageous pharmacological properties which allow their use in therapeutics, notably for treating neurodegenerative disorders or pain.